by NImmune Biopharma | Apr 10, 2025 | Press Release
Download Press Release Omilancor is a once-daily, oral, best- and first-in-class therapy in Phase 3 clinical development for ulcerative colitis, with multiple I&I indications in progress New results to be presented in DDW elucidate omilancor’s path to patients and...
by NImmune Biopharma | Jan 13, 2025 | Press Release
Download Press Release First-in-human clinical trial of NIM-1324 met all primary and secondary endpoints Daily oral NIM-1324 treatment confirmed as well-tolerated and safe with no dose-limiting toxicities Oral treatment with NIM-1324 validated to engage LANCL2 in...
by NImmune Biopharma | Oct 23, 2024 | Press Release
Download Press Release Transaction is highly shareholder value accretive, enabling the potential acceleration of the global registration directed Phase 3 program in ulcerative colitis, the Phase 2 program in Crohn’s disease, and additional I&I indications Global...
by NImmune Biopharma | Oct 7, 2024 | Press Release
Download Press Release NIM-1324 validated as the first LANCL2 drug with therapeutic efficacy in systemic inflammation in three mouse models of lupus to support immune tolerance A mechanism of LANCL2 newly discovered in phagocytes that combines with established...
by NImmune Biopharma | Sep 16, 2024 | Press Release
Download Press Release BLACKSBURG, VA. – September 16, 2024 – NImmune Biopharma (“NImmune”), a Phase 3 precision inflammation & immunology (I&I) biopharmaceutical company that develops novel best-in-class biomarker-driven immunoregulatory...
